TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1636468

Group type: EXPERIMENTAL
Intervention: Alcohol Beverage
Number of subjects: 48

Group type: COMPARATOR
Intervention: Lemonade Beverage
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High-Risk Imagery
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Low-Risk Imagery
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Alcohol/High-Risk Imagery
Number of subjects: 48
Study: 6148991

Group type: EXPERIMENTAL
Intervention: Pindolol 5 mg thrice daily
Number of subjects: 15

Group type: COMPARATOR
Intervention: Atenolol 100 mg daily
Number of subjects: 15
Study: 31070712

Group type: EXPERIMENTAL
Intervention: High-DHA enteral feeds (∼1% total fatty acids)
Number of subjects: 657

Group type: COMPARATOR
Intervention: Standard-DHA enteral feeds (∼0.3% total fatty acids)
Number of subjects: 657
Study: 30098152

Group type: EXPERIMENTAL
Intervention: Anlotinib (12 mg/d)
Number of subjects: 606

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 606
Study: 27074067

Group type: EXPERIMENTAL
Intervention: Laminectomy with posterolateral instrumented fusion
Number of subjects: 66

Group type: COMPARATOR
Intervention: Decompressive laminectomy alone
Number of subjects: 66
Study: 25014743

Group type: COMPARATOR
Intervention: Maternal feeding beliefs (measured at 4 months)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Maternal awareness of infant hunger and satiety cues (measured at 4 months)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Mothers' use of Pressure to eat (mediating factor)
Number of subjects: 244
Study: 22768723

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19836027

Group type: EXPERIMENTAL
Intervention: Guidelines for management of acute gastroenteritis (AGE) training for pediatricians (group A)
Number of subjects: 1309

Group type: COMPARATOR
Intervention: No specific training in guidelines for management of acute gastroenteritis (group B)
Number of subjects: 1309
Study: 17827963

Group type: EXPERIMENTAL
Intervention: Fluoride varnish (Fluor Protector)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Placebo varnish
Number of subjects: 273
Study: 16119035

Group type: EXPERIMENTAL
Intervention: BUD (400 microg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: FP (250 microg/day)
Number of subjects: 100
Study: 12495258

Group type: EXPERIMENTAL
Intervention: High-calcium skim milk enriched with magnesium (milk group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Apple drink (apple group)
Number of subjects: 50
Study: 9817150

Group type: EXPERIMENTAL
Intervention: Bronchial biopsies with multiple measurements of reticular basement membrane (RBM) thickness
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Bronchial biopsies with counts of inflammatory cells
Number of subjects: 18
Study: 7759173

Group type: EXPERIMENTAL
Intervention: Daily dosing of methadone
Number of subjects: 45

Group type: COMPARATOR
Intervention: Twice daily dosing of methadone
Number of subjects: 45
Study: 2655847

Group type: EXPERIMENTAL
Intervention: New pacemakers
Number of subjects: 70

Group type: COMPARATOR
Intervention: Refurbished pacemakers
Number of subjects: 70
Study: 400806

Group type: EXPERIMENTAL
Intervention: 100 mg dapsone daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: 100 mg dapsone and 600 mg rifampicin daily for 6 months
Number of subjects: 0
Study: 31324343

Group type: EXPERIMENTAL
Intervention: Risankizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 0
Study: 28114723

Group type: EXPERIMENTAL
Intervention: Respiratory muscle endurance (RME) training for 8 weeks using an RME training device.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard chest physiotherapy (control) for 8 weeks.
Number of subjects: 22
Study: 26395085

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (50 mg/kg bolus followed by 15 mg/kg/h infusion)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (Ringer acetate)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 80
Study: 24191966

Group type: EXPERIMENTAL
Intervention: Aerobic endurance training (AET) - 45 minutes of walking/running at 60% heart rate reserve, 3 times per week for 26 weeks.
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Strength endurance training (SET) - 8 machine-based exercises (2 sets of 15 repetitions with 100% of the 20 repetition maximum), 3 times per week for 26 weeks.
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no exercise training).
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: All groups (AET, SET, and controls).
Number of subjects: 102
Study: 21236344

Group type: EXPERIMENTAL
Intervention: exemestane (EXE) 25 mg daily and celecoxib (CXB) 400 mg twice daily (group A)
Number of subjects: 82

Group type: COMPARATOR
Intervention: exemestane (EXE) 25 mg daily (group B)
Number of subjects: 82

Group type: COMPARATOR
Intervention: letrozole (LET) 2.5 mg daily (group C)
Number of subjects: 82
Study: 19125307

Group type: EXPERIMENTAL
Intervention: Band ligation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Injection therapy
Number of subjects: 18
Study: 17512780

Group type: EXPERIMENTAL
Intervention: Pramipexole 0.25mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 15456093

Group type: EXPERIMENTAL
Intervention: 200 mg/d ritonavir
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 400 mg/d ritonavir
Number of subjects: 37
Study: 11466986

Group type: EXPERIMENTAL
Intervention: CRP rapid test group
Number of subjects: 812

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 812
Study: 9126686

Group type: EXPERIMENTAL
Intervention: Systemic interferon alpha‐2b
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 8472625

Group type: EXPERIMENTAL
Intervention: Subcutaneous human proinsulin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Insulin zinc suspension
Number of subjects: 6

Group type: COMPARATOR
Intervention: Inactive diluent (control)
Number of subjects: 6
Study: 3676211

Group type: EXPERIMENTAL
Intervention: Alcohol (mean intake 18.4 g/d) for 4 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Abstinence from alcohol for 4 weeks
Number of subjects: 100
Study: 31305949

Group type: EXPERIMENTAL
Intervention: Solution-focused approach (intervention group)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Existing treatment (control group)
Number of subjects: 41
Study: 30439834

Group type: EXPERIMENTAL
Intervention: Facilitated care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-facilitated care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General practitioners (GPs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mental health professionals (MHPs)
Number of subjects: 0
Study: 27165587

Group type: EXPERIMENTAL
Intervention: PS + continuous inhalation of budesonide aerosol
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: PS + budesonide solution
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: PS + single inhalation of budesonide aerosol
Number of subjects: 184

Group type: COMPARATOR
Intervention: PS alone
Number of subjects: 184
Study: 24574834

Group type: EXPERIMENTAL
Intervention: Propofol sedation during upper gastrointestinal endoscopy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no propofol)
Number of subjects: 20
Study: 22752068

Group type: EXPERIMENTAL
Intervention: Weightlifting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 20962212

Group type: EXPERIMENTAL
Intervention: Canakinumab (300 mg, subcutaneously)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 51
Study: 17490781

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 366

Group type: COMPARATOR
Intervention: Adjusted OAD therapy
Number of subjects: 366
Study: 15699946

Group type: EXPERIMENTAL
Intervention: Cardioversion with subsequent use of antiarrhythmic drugs for maintenance of sinus rhythm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antithrombotic drugs (warfarin and aspirin)
Number of subjects: 0
Study: 15124545

Group type: EXPERIMENTAL
Intervention: Hyperthermia between 40 and 45 degrees C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microwave superficial hyperthermia, thermo ablation using radiofrequencies or high focused ultrasound, loco regional heating by intraperitoneal perfusion or by external circulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thermo-sensitive liposomes for carrying and targeting chemotherapeutics and gene therapies
Number of subjects: 0
Study: 10912216

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: TCA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8843528

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy
Number of subjects: 13

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 13
Study: 1604260

Group type: EXPERIMENTAL
Intervention: Low level laser (GaAs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo laser
Number of subjects: 30
Study: 6331482

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg daily)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Propranolol (180 mg daily)
Number of subjects: 54
Study: 3774444

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31720816

Group type: EXPERIMENTAL
Intervention: gemcitabine plus cisplatin (GP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: fluorouracil plus cisplatin (FP)
Number of subjects: 0
Study: 31283977

Group type: EXPERIMENTAL
Intervention: Probe-trial testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adduction testing
Number of subjects: 0
Study: 28867319

Group type: EXPERIMENTAL
Intervention: Hands-on training on microanastomosis using Silastic tubes
Number of subjects: 10

Group type: COMPARATOR
Intervention: Didactic and visual training on end‐to‐end microvascular anastomosis
Number of subjects: 10
Study: 25555390

Group type: EXPERIMENTAL
Intervention: Morning exercise sessions
Number of subjects: 35

Group type: COMPARATOR
Intervention: Afternoon exercise sessions
Number of subjects: 35
Study: 23848030

Group type: EXPERIMENTAL
Intervention: Ziziphus jujuba (ZJ) fruit powder 5 grams three times a day for one month
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo powder 5 grams three times a day for one month
Number of subjects: 70
Study: 21798838

Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair (CR group)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Isolated acromioplasty-tenotomy (AT group)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Healing in CR group
Number of subjects: 142
Study: 18292454

Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.25%
Number of subjects: 60

Group type: COMPARATOR
Intervention: lidocaine 2% with epinephrine
Number of subjects: 60
Study: 16575275

Group type: EXPERIMENTAL
Intervention: Individual lifestyle advice intervention
Number of subjects: 1270

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1270
Study: 12601559

Group type: EXPERIMENTAL
Intervention: Computer-based version of the Strengths and Difficulties Questionnaire (SDQ)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Paper-based version of the Strengths and Difficulties Questionnaire (SDQ)
Number of subjects: 214
Study: 11121909

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg o.m. and tinidazole 500 mg b.d. during the first 3 days of pantoprazole therapy (early group, n=50)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg o.m. and tinidazole 500 mg b.d. during the last 3 days of pantoprazole therapy (late group, n=50)
Number of subjects: 100
Study: 9028644

Group type: EXPERIMENTAL
Intervention: Bromocriptine (BC)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 7
Study: 1532117

Group type: EXPERIMENTAL
Intervention: Procaterol aerosol (10 micrograms/inhalation), 2 inhalations t.i.d.
Number of subjects: 333

Group type: COMPARATOR
Intervention: Albuterol (salbutamol) aerosol (100 micrograms/inhalation), 2 inhalations t.i.d.
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Procaterol
Number of subjects: 333

Group type: COMPARATOR
Intervention: Albuterol
Number of subjects: 333
Study: 3856692

Group type: EXPERIMENTAL
Intervention: Gemfibrozil therapy
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 30099422

Group type: EXPERIMENTAL
Intervention: Basic medical treatment and allergen-specific immunotherapy (ASIT)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Basic medical treatment only
Number of subjects: 104
Study: 26644526

Group type: EXPERIMENTAL
Intervention: Low-dose morphine
Number of subjects: 240

Group type: COMPARATOR
Intervention: Weak opioids
Number of subjects: 240
Study: 24850618

Group type: COMPARATOR
Intervention: Neuromuscular training programme (NMT)
Number of subjects: 799
Study: 22423133

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole prophylaxis continued (n = 452)
Number of subjects: 836

Group type: COMPARATOR
Intervention: Cotrimoxazole prophylaxis discontinued (n = 384)
Number of subjects: 836
Study: 20441717

Group type: EXPERIMENTAL
Intervention: Olanzapine ODT (10 mg od, 8 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Olanzapine OST (10 mg od, 8 days)
Number of subjects: 12
Study: 18821366

Group type: EXPERIMENTAL
Intervention: Body image intervention
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 81
Study: 15828904

Group type: EXPERIMENTAL
Intervention: Oral calcium carbonate alone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Oral calcium carbonate plus vitamin D sterol (calcitriol or alfacalcidol)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral calcium carbonate plus vitamin D sterol
Number of subjects: 50
Study: 12478069

Group type: EXPERIMENTAL
Intervention: HIV co‐culture of PBMC
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Blood HIV DNA assay
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rectal biopsy HIV DNA
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rectal biopsy HIV RNA
Number of subjects: 40
Study: 9917117

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation self-management group based on a structured treatment and teaching program and INR self-monitoring
Number of subjects: 179

Group type: COMPARATOR
Intervention: Conventional care as provided by family physicians
Number of subjects: 179
Study: 7775627

Group type: EXPERIMENTAL
Intervention: Prednisone (20 mg daily for 1 week)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Yohimbine (0.125 mg/kg bolus, 0.001 mg.kg‐1.min‐1 infusion)
Number of subjects: 15
Study: 2089128

Group type: EXPERIMENTAL
Intervention: Dantrolene sodium
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 35406

Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH), 40 mg single dose
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31011711

Group type: EXPERIMENTAL
Intervention: Nonacog beta pegol (N9‐GP)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Recombinant factor IX‐Fc fusion protein (rFIXFc)
Number of subjects: 15
Study: 29798207

Group type: EXPERIMENTAL
Intervention: Nasal spray allergen blocker combined with oral antihistamine (citrate tablets)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Physiological seawater combined with citrate sheet (control group)
Number of subjects: 90
Study: 27565398

Group type: EXPERIMENTAL
Intervention: Smoking Treatment and Anxiety Management Program (STAMP)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Standard Cessation Program (SCP)
Number of subjects: 384
Study: 24499130

Group type: EXPERIMENTAL
Intervention: Koru mindfulness program
Number of subjects: 90
Study: 22261467

Group type: EXPERIMENTAL
Intervention: Single-port total laparoscopic hysterectomy (Octoport™)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional four-port total laparoscopic hysterectomy
Number of subjects: 56
Study: 19129341

Group type: EXPERIMENTAL
Intervention: Spiritual striving
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Acceptance coping
Number of subjects: 180

Group type: COMPARATOR
Intervention: Social support
Number of subjects: 180
Study: 17195831

Group type: EXPERIMENTAL
Intervention: 2% mepivacaine with 1:100,000 epinephrine
Number of subjects: 35

Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 35
Study: 15164511

Group type: EXPERIMENTAL
Intervention: Standard therapy (ST) + amino acids complex (AAC) (one tablet of 70 mg 3 times a day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Standard therapy (ST) + AAC sublingually (one tablet of 70 mg 3 times a day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard therapy (ST) + placebo
Number of subjects: 60
Study: 11668360

Group type: EXPERIMENTAL
Intervention: Dipyrone (600 mg oral dose)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: LSS models based on three sampling points (1.5, 4 and 24 h)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: LSS models for bioequivalence assessment
Number of subjects: 12
Study: 9482291

Group type: EXPERIMENTAL
Intervention: High-dose isosorbide dinitrate (3 mg bolus administered intravenously every 5 min)
Number of subjects: 110

Group type: COMPARATOR
Intervention: High-dose furosemide (80 mg bolus administered intravenously every 15 min) plus low-dose isosorbide dinitrate (1 mg/h, increased every 10 min by 1 mg/h)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: High-dose isosorbide dinitrate
Number of subjects: 110

Group type: COMPARATOR
Intervention: High-dose furosemide plus low-dose isosorbide dinitrate
Number of subjects: 110
Study: 8305277

Group type: EXPERIMENTAL
Intervention: Gadodiamide injection at a dose of 0.1 mM/kg (n = 5)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Gadodiamide injection at a dose of 0.3 mM/kg (n = 7)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Gadopentetate dimeglumine at a dose of 0.1 mM/kg (n = 6)
Number of subjects: 12
Study: 3071485

Group type: EXPERIMENTAL
Intervention: Diet plus moderate exercise (3-mile walk, twice a week group sessions, once a week individual sessions)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Diet plus exercise (3-mile walk, 3 times/week group sessions, once a week individual sessions)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Diet only (maintain current low level of activity)
Number of subjects: 25
Study: 29982544

Group type: EXPERIMENTAL
Intervention: Combined 2 × 1000 mg/d omega-3 fatty acid and 50,000 IU/biweekly cholecalciferol supplement
Number of subjects: 53
Study: 27046347

Group type: EXPERIMENTAL
Intervention: Stent-retriever thrombectomy in combination with IV t-PA
Number of subjects: 0

Group type: COMPARATOR
Intervention: IV t-PA alone
Number of subjects: 0
Study: 24856854

Group type: EXPERIMENTAL
Intervention: Web‐based self‐management exercise and diet intervention program (n=29)
Number of subjects: 59

Group type: COMPARATOR
Intervention: 50‐page educational booklet on exercise and diet (n=28)
Number of subjects: 59
Study: 22512875

Group type: EXPERIMENTAL
Intervention: Inorganic sunscreen with SPF 8 at 0 mg cm(‐2) thickness
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Inorganic sunscreen with SPF 8 at 0.5 mg cm(‐2) thickness
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Inorganic sunscreen with SPF 8 at 1 mg cm(‐2) thickness
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Inorganic sunscreen with SPF 8 at 1.5 mg cm(‐2) thickness
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Inorganic sunscreen with SPF 8 at 2 mg cm(‐2) thickness
Number of subjects: 37
Study: 20080810

Group type: EXPERIMENTAL
Intervention: Children born at 37 weeks gestation
Number of subjects: 13824

Group type: EXPERIMENTAL
Intervention: Children born at 38 weeks gestation
Number of subjects: 13824

Group type: EXPERIMENTAL
Intervention: Children born at 42 weeks gestation
Number of subjects: 13824

Group type: EXPERIMENTAL
Intervention: Children born at 43 weeks gestation
Number of subjects: 13824

Group type: EXPERIMENTAL
Intervention: Children born small for gestational age (<10th percentile)
Number of subjects: 13824

Group type: COMPARATOR
Intervention: Children born large for gestational age (>90th percentile)
Number of subjects: 13824
Study: 18843942

Group type: EXPERIMENTAL
Intervention: Five sessions of Behavioral Counseling
Number of subjects: 46

Group type: COMPARATOR
Intervention: One session of Behavioral Counseling
Number of subjects: 46
Study: 16210713

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplementation (MMN group)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Iron and folic acid supplementation (IFA group)
Number of subjects: 197
Study: 12126264

Group type: EXPERIMENTAL
Intervention: Telmisartan monotherapy (40 or 80 mg)
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Telmisartan + HCTZ 12.5 mg
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Telmisartan + HCTZ 25 mg
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Telmisartan + another antihypertensive + HCTZ
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Telmisartan monotherapy
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Telmisartan + HCTZ
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 888
Study: 8788268

Group type: EXPERIMENTAL
Intervention: Glutamine-supplemented TPN
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard TPN
Number of subjects: 44
Study: 1701072

Group type: EXPERIMENTAL
Intervention: Aprotinin (2 x 10(6) KIU bolus before surgery, continuous infusion of 5 x 10(5) KIU/h during surgery, and additional 2 x 10(6) KIU to pump prime)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (placebo treatment)
Number of subjects: 40
Study: 7418949

Group type: EXPERIMENTAL
Intervention: Guanabenz (24 mg daily)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 30933948

Group type: EXPERIMENTAL
Intervention: Connective Tissue Manipulation Group (CTMG)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 210
Study: 28732519

Group type: EXPERIMENTAL
Intervention: General skin-care advice plus emollients applied daily for the first year of life
Number of subjects: 1400

Group type: COMPARATOR
Intervention: General infant skin-care advice
Number of subjects: 1400
Study: 24916884

Group type: EXPERIMENTAL
Intervention: High-intensity (HI, 74% of 1‐repetition maximum)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Middle-intensity (MI, 54% 1RM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Middle-intensity no-relaxation exercise (MIR, 54% 1RM)
Number of subjects: 10